NCT00651703 - Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL

CYT004-MelQbG10 + Montanide

BIOLOGICAL

CYT004-MelQbG10 + Montanide + Imiquimod

BIOLOGICAL

CYT004-MelQbG10 + Imiquimod

BIOLOGICAL

CYT004-MelQbG10 intra nodal injection

Trial Locations (2)

Ludwig Institute for Cancer Research; CHUV, Lausanne

Dermatologische Klinik, UniversitätsSpital Zürich, Zurich